Podcasts

Drs Kruse and O’Brien highlight the various roles of imaging modalities in breast cancer diagnosis and treatment decision-making.

David Carbone, MD, PhD, discusses the 6-year data from the phase 3 CheckMate 9LA trial (NCT03215706).

Dr Sammons discusses the rationale for and findings from a phase 2 study evaluating pumitamig in patients with locally advanced or metastatic TNBC.

Rashmi Chugh, MD, discusses the ongoing development of the investigational γ-secretase inhibitor varegacestat for patients with desmoid tumors.

Drs Matulonis and Campos discuss the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.

Rachna T. Shroff, MD, MS, FASCO, and Kristen Spencer, DO, discuss factors weighed when navigating first-line chemotherapy selection in pancreatic cancer.

Drs Armstrong and Tawagi highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium in prostate, bladder, and kidney cancers.

Philippos Costa, MD, and Hari Deshpande, MD, answer common questions about chondrosarcoma staging, diagnosis, surgery, and future research avenues.

Alexander I. Spira, MD, PhD, FACP, FASCO, discusses the FDA approval of subcutaneous amivantamab for patients with EGFR-mutated NSCLC.

Drs Camidge and Kantor reflect on Dr Kantor's decades-long career in oncology, which was propelled by a devotion to patients.

Nicholas Short, MD, discusses TKIs like ponatinib and combining them with other treatments for ALL.

Christopher Lieu, MD, expands on current treatment strategies and factors informing third-line sequencing decisions in mCRC.

Dr Bardia discusses key findings from the phase 3 lidERA Breast Cancer study of giredestrant in estrogen receptor–positive, HER2-negative breast cancer.

Dr Schrag weighed in on where oncology stands today and previewed the goals she hopes to advance during her tenure as ASCO President in 2027-2028.

Drs Whitman and Patel discuss the evolving treatment paradigm for patients with CSCC, emphasizing the role of neoadjuvant and adjuvant immunotherapies.

Dr Jhaveri discusses the evaluation of sacituzumab govitecan earlier in the HR-positive, HER2-negative metastatic breast cancer treatment paradigm.

Andrew Lipsky, MD, discusses data with pirtobrutinib in relapsed/refractory CLL and the effect of its FDA approval on sequencing decisions for this disease.

Adam Fox, MD, and Cynthia A. Schandl, MD, PhD, examined the expanding role of biomarker testing and genomic profiling in NSCLC across disease stages.

Sikander Ailawadhi, MD, and Beth Faiman, CNP, PhD, discuss the ongoing development of subcutaneous isatuximab administration via an on-body injector for patients with multiple myeloma.

Dr Phillips discusses updated data from the EPCORE NHL-1 trial investigating epcoritamab monotherapy in patients with relapsed/refractory LBCL.

Breast cancer experts discuss adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways.

Dr Bardia discusses the ELEGANT study of elacestrant in estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.

John O. Mascarenhas, MD, details the investigation of novel targeted therapies in patients with myeloproliferative neoplasms.